Advertisement
Research Article

Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice

  • Hayat Caidi,

    Affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America

    X
  • Jennifer L. Harcourt,

    Affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America

    X
  • Ralph A. Tripp,

    Affiliation: College of Veterinary Medicine, Department of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America

    X
  • Larry J. Anderson,

    Affiliation: Division of Pediatric Infectious Diseases, Emory Children’s Center, Atlanta, Georgia, United States of America

    X
  • Lia M. Haynes mail

    loh5@cdc.gov

    Affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America

    X
  • Published: December 27, 2012
  • DOI: 10.1371/journal.pone.0051485

About the Authors

Hayat Caidi, Jennifer L. Harcourt, Lia M. Haynes
National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America
Ralph A. Tripp
College of Veterinary Medicine, Department of Infectious Diseases, University of Georgia, Athens, Georgia, United States of America
Larry J. Anderson
Division of Pediatric Infectious Diseases, Emory Children’s Center, Atlanta, Georgia, United States of America

Corresponding Author

Email: loh5@cdc.gov

Competing Interests

The authors have the following interests: R. Tripp, L. Haynes and L. Anderson have a licensing agreement related to the monoclonal antibody, 131-2G, with Trellis Biosciences. R. Tripp is a PLOS ONE Editorial Board Member. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: LH LJA RT. Performed the experiments: HC JLH. Analyzed the data: HC JLH LH. Contributed reagents/materials/analysis tools: LH HC RT. Wrote the paper: HC LH. Carried out the experimental design and animal studies: HC. Interpreted the results: HC. Designed and carried out the in vitro experiments: JLH. Co-worked on associated data collection and their interpretation: JLH. Defined the research theme, study conception, and experimental design: LH. Provided contribution to study conception: LJA RT. Completed critical revision of the manuscript: LH LJA RT.